Kromek is pioneering digital colour imaging for x-rays and has brought ground-breaking innovation to materials technology and advanced 3D imaging, that will literally change the way in which we see the world.


The Company specialises in making semiconductor materials within the Cadmium Telluride family. These materials have significant applications as detectors of x-rays and gamma rays, notably in medical imaging, security screening, industrial inspection and space exploration, allowing for very precise identification of materials.



Cadmium Zinc Telluride is also the material of choice as a substrate for the fabrication of infrared detectors in both civilian and military markets. In addition to its range of semiconductor materials, detector packages and non imaging detection systems Kromek also supplies x-ray imaging packages with multi view capabilities.

These x-ray display platforms provide real 3D x-ray imaging for the first time without specialist viewing equipment. When photogrammetric algorithms are applied to these images, three dimensional co-ordinate data is produced.

Kromek Group is listed on London's alternative Investment Market, AIM. Its ordinary shares carry the symbol KMK. Kromek Group plc is incorporated in England and Wales under the Companies Act 2006 (registration number 8661469). Its main countries of operation are the United Kingdom and the United States.

http://www.kromek.com/

Kromek, which designs, develops and produces x-ray imaging and radiation detection products using its core cadmium zinc telluride technology, could be set for a bonanza year in 2014 as a new European Union directive comes in at the end of January requiring all European airports to screen liquids, aerosols and gels presented at airport security with EC approved equipment.


http://www.proactiveinvestors.co.uk/columns/broker-spotlight/14941/broker-round-up-serco-conviviality-retail-kromek-rightmove-wood-group-14941.html

Up 8.27%

dc nice one, our TP is 100p, given New Year tips.

Cheers halifax.

Closed up 10.53%

Scan time halved for Kromek Identifier in new ECAC accreditation - 05 December 2013

Kromek has received certification from the European Civil Aviation regulatory authority, ECAC, for its new generation of liquid explosive detecting bottle scanners, the Kromek Identifier. The new Identifier models halve the previous scanning time, allowing the screening process to be completed in ten seconds, while still retaining the highest performance category in its class.



Commenting on the announcement, Kromek CEO Dr Arnab Basu said: "The accreditation for our new, shorter-cycle Identifier bottle scanner from ECAC proves the effectiveness of our technology and also reinforces our continued commitment to work in partnership with our customer base to improve our system and the quality of the user experience."

Dr Basu added: "What makes the Identifier unique is its ability to scan metal cans, Tetra Pak and foil pouches, in addition to all types of glass and plastic containers; this means the Kromek Identifier is the only ECAC Standard 3 approved system that can scan every container type with a simple one button operation."

Kromek also announced it has secured a number of orders from UK and European airports for the Identifier. As well as receiving orders from nine UK Airports, new orders have been secured to supply airports in Portugal, Cyprus, and Belgium, as well as existing installations to airports in Finland, Germany and Australia.

These orders coincide with the phase 1 implementation of a 3 phase International Civil Aviation Organization pathway, mandated in the EU, from January 2014 to January 2016. Phase 1 will initially mandate that all EU airports provide the security screening equipment needed to allow the passage of liquids through airports for connecting passengers. Ultimately, the objective of the EU and the rest of the world, is to relax travel restrictions on the passage of all liquids, aerosols and gels

sp moving higher 78.5p up 6.8%

UP over 8% :-))

Article in Shares - Lift off for Kromek.

Looser EU aviation regulations with regard to liquids on flights across Europe could drive demand for Kromek's x-ray bottle scanner technology. Analysts believe many airports will introduce the new kit through 2014 and stoke further share gains.

Had wondered if Kromek was capturing the US market, clearly they are -


Kromek completes second US acquisition


Tuesday, 23 April 2013


Multi-award winning Anglo-American platform technology firm Kromek, has today announced it has successfully completed its second US acquisition, that of Pennsylvania-based Endicott Interconnect Detection and Imaging Systems (EIDIS), a division of Endicott Interconnect Technologies Inc.

Formerly known as eV Products, EIDIS becomes a fully owned subsidiary of the Kromek Group and will be trading as eV Products Inc.

eV Products operates in a similar area to Kromek; it was the pioneer and has over two decades of experience in Cadmium Zinc Telluride (CZT) materials and detectors. eV Products remains a leading global manufacturer of CZT detectors that can be integrated into custom designed OEM components and subassemblies for medical imaging, nuclear, industrial and homeland security markets.

Employing over 40 staff in a 3,000m2 facility in Saxonburg, the company has a large suite of products, and brings with it a very wide range of skills, competencies, capabilities, capacity and IP.

Kromek CEO, Dr Arnab Basu said: “There are compelling reasons for making this acquisition, not least that it put puts Kromek Group in a strong position in the spectral radiation detection market by having the widest breadth of technology for detector materials production and manufacturing capability, and is further complemented by the ASIC and electronics capabilities of Kromek’s first acquisition, California-based NOVA, and the existing wide breadth of expertise of Kromek in the UK.”

“While Kromek’s business model has recently been focused on developing end-user products in nuclear and explosive detection market, EIDIS had remained focused on OEM components and subassemblies-based product range.”

“Combining Kromek and eV Products technology and IP will create an unparalleled company in the CZT industry, meeting the needs of customers in the medical, security, industrial and defense industries.”

Dr Basu added: “The Group now employs more than 100 people across its three facilities. This means that together with our worldwide distributors, Kromek is able to fully service a growing global customer base that reaches across the US, Europe, Asia, Pacific and Australia.

“This acquisition further demonstrates our continued commitment to expand business in the US; it’s part of a planned strategy of growth, expanding to meet growing customer demands in the US market. This acquisition also establishes Kromek’s ability to provide a domestic source and security of supply for US customers”

Tech sector tipped for even bigger things in 2014

By Jamie Nimmo

December 29 2013, 9:01am


Broker Panmure Gordon‘s top picks for 2014 also include many tech shares.

X-ray imaging company Kromek (LON:KMK) has fared well since offering shares to the public in October, rising 17p to 68p. And Panmure thinks it will continue to soar to 92p in 2014, with plenty to satisfy of news on the way.



http://www.proactiveinvestors.co.uk/companies/news/64480/tech-sector-tipped-for-even-bigger-things-in-2014-64480.html

Strong purchasing today.

Up just under 10% :-))

MBE for Kromek chief executive Dr Arnab Basu

http://www.darlingtonandstocktontimes.co.uk/news/10904948.MBE_for_Kromek_chief_executive_Dr_Arnab_Basu/?ref=var_0

Half Yearly Report

http://www.moneyam.com/action/news/showArticle?id=4735435

some potential no doubt but sales need to increase dramatically.

The global medical imaging market was valued at $24bn in 2013 and is expected to reach an annual value of $35bn by 2019. Within that market, the CT scanner and nuclear imaging segments, two of Kromek’s key areas, are expected to show the fastest rate of growth. The overall market for CT scanners is estimated to grow to a value of $5.1bn per annum by 2017, offering major opportunities and potential for growth for Kromek.

The European Civil Aviation Conference regulations which will bring about a partial lifting of the ban on the carriage of liquids on board aircraft by 31 January 2014, is driving demand for the Group’s bottle scanner product. It is thought that the addressable market for this product over the next three years is worth around £150m.

Kromek Group to showcase at the London Innovators and Investors Forum 2014

StockMarketWire.com

Kromek Group Plc (KMK) (LON:KMK) will be showcasing their company at the Shares Magazine/Cenkos Innovators and Investors Forum in London on 4th February 2014. This successful event is a one day conference and expo showcasing up to 40 leading technology companies in front of an invited audience of institutional and private investors. Companies present include: Allocate Software, Angle, Avanti Communications, Bango, Bond International Software, Brady, Cenkos Securities, CML Microsystems, Earthport, Eleco, Enables IT, Escher Group Holdings, Filtronic, Forbidden Technologies, Globo, Imperial Innovations, incadea, InternetQ, KBC Advanced Technologies, Kromek Group, Optimal Payments, Quindell, Regenersis, Rightster,Shares Magazine, StatPro and Transense Technologies. More companies to be announced. More details at: http://www.msmconferences.com/event/iif2014

At 3:33pm: (LON:KMK) Kromek Group PLC share price was +0.25p at 79.25p

Organised in partnership with Cenkos Securities and Shares magazine, the second Innovators & Investors Forum will take place on 4th February 2014 at the Business Design Centre, London N1.

The event aims to showcase up to 40 leading innovative and imaginative technology-led firms and to bring them together with the investment community. It combines both a company expo and an educational conference where delegates learn about a range of investment opportunities.

REGISTER NOW

Why attend?

This event gives you a platform to meet under one roof up to 40 technology-led companies, hear their messages during presentation seminars and engage in discussions with them on their stands.

The event is supported with an extensive conference program, including keynote speakers and company presentations.



Companies already confirmed for the 4th February 2014 include:

Allocate Software
Angle
Avanti Communications
Bango
Bond International Software
Brady
Cenkos Securities
CML Microsystems
Deltex Medical
Earthport
Eleco
Enables IT
Escher Group Holdings
Filtronic
Forbidden Technologies
Globo
Imperial Innovations
incadea
InternetQ
ITM Power
KBC Advanced Technologies
Kromek Group
Optimal Payments
Plastics Capital
Quindell
Regenersis
Rightster
StatPro
Transense Technologies


CONFERENCE AGENDA

The following session is dedicated to a mix of institutional investor and private investors.

11:40 Company presentation - Colin Miles, VP, Corporate Relations - InternetQ

11:55 Company presentation - Hank Uberoi, CEO - Earthport

12:10 Company presentation - Quindell

12:25 Company presentation - Dr Nigel Pitchford, Chief Investment Officer - Imperial Innovations

12:40 Lunch

The afternoon sessions are dedicated to private investors.

14:00 Keynote address - Richard Penny, Senior Fund Manager - Legal and General UK Alpha Trust

14:15 Russ Mould, Editor - Shares Magazine

14:30 Company presentation - Kromek Group

14:45 Company presentation - Joel Leonoff, President & CEO - Optimal Payments

15:00 Company presentation

15:15 Company presentation - Charlie Muirhead, CEO and Founder - Rightster

15:30 Company presentation - Caroline Brown, Executive Director & CFO - KBC Advanced Technologies

15:45 Coffee

16:15 Company presentation - Andrew Fabian, Group Finance Director - StatPro

16:30 Company presentation

16:45 Company presentation

17:00 Company presentation - Jonathan O’Connell, CFO - Escher Group Holdings

17:15 Company presentation - ITM Power

17:30 Close

The exhibition will be open from 10:45 to 17:30.

Coffee / lunch will be served within the exhibition.


This agenda is subject to change and alterations. More companies to be announced soon.

REGISTER NOW

The exhibition will be open from 10:45 to 17:30.

Coffee / lunch will be served within the exhibition.



This agenda is subject to change and alterations. More companies to be announced soon.



EXHIBITION

The exhibition will be open from 10:45 to 17:30.

Coffee / lunch will be served within the exhibition.



Dress code: business attire




VENUE
Business Design Centre
52 Upper Street
Islington
London N1 0QH

http://www.businessdesigncentre.co.uk/

Access map: http://www.businessdesigncentre.co.uk/VisitingUs

Closest tube station: Angel (3 min. walk) - Northern Line





SPONSOR


Cenkos Securities is an independent specialist securities firm focused on UK small and mid-cap companies.
We aim to be entrepreneurial, whilst seeking to establish long-term relationships with corporate and institutional clients.
Our directors and partners have on average more than 25 years' experience in the UK securities market. They have pioneered and led some of the most successful and innovative transactions in the UK securities market over the last decades.

REGISTER NOW

WATCH: Dr Arnab Basu, CEO of Kromek, provides an overview to BRR at the Innovators & Investors Forum

Click here to watch

New Orders Received in Medical Imaging

RNS


RNS Number : 0459B

Kromek Group PLC

27 February 2014






Embargoed until: 0700hrs, 27 February 2014



Kromek Group plc

("Kromek" or "the Company")

New Orders Received in Medical Imaging



Kromek, a supplier of patented radiation detection technologies to the medical, security and nuclear markets, announces that it has secured $845,000 of new orders to supply radiation detectors and integrated electronic components to a globally leading Original Equipment Manufacturer ('OEM') operating in the Dual Energy X-ray Bone Mineral Densitometry ('DEXA BMD') market. The total booking this fiscal year from this customer now exceeds $1.25 million.

DEXA BMD is the most accurate imaging technique to diagnose the strength and health of bones, allowing clinicians to accurately detect, monitor and treat Osteoporosis in patients. DEXA BMD is another medical diagnostic imaging modality where improved x-ray detection and imaging detail helps early diagnostics and intervention, which enables healthcare providers to operate more efficiently and manage costs against a backdrop of global healthcare budget pressures.

The new orders to supply detection components based on Kromek's Cadmium Zinc Telluride ('CZT') technology, are in addition to an existing contract the Company has in place with the OEM partner, in a global BMD market expected to surpass $895 million by 2017.

Commenting on the announcement, Arnab Basu, CEO of Kromek, said: "This latest order from this existing OEM partner builds on an important international relationship as we continue to see growth through expanding our geographic reach, particularly in Asia.

"Our work in BMD helps clinicians to detect and treat Osteoporosis earlier and is further validation of our technology and its capabilities in improving the efficacy of medical scanning technologies. This latest success adds to the encouraging progress we have seen in the wider medical imaging space, as evidenced by our announcement in November 2013 of a $990,000 contract to supply components to the nuclear medicine market, alongside the up to $5.3 million development contract we received in the x-ray CT scanning space. We have multiple blue-chip customers in the medical imaging sector and are seeing excellent traction in the adoption of our components. We look forward to announcing further progress in due course."

-ends-

Trading Statement

RNS


RNS Number : 3994D

Kromek Group PLC

28 March 2014




28 March 2014

Kromek Group plc

("Kromek" or "the Company")

Trading Statement

Kromek, a supplier of patented radiation detection technologies to the medical, security and nuclear markets, provides the following update on trading ahead of its year end on 30 April 2014.

Despite strong revenue growth year-on-year, the Company expects revenue for the period to be significantly below current market expectations. The shortfall for the year is due to a delay in a number of large contracts. Specifically, these include UK and US Government programmes, orders from the Japanese market for nuclear detection products and further large orders in the medical and security markets.

Furthermore it has taken longer than expected to set up distribution channels for nuclear radiation products, which are now in place in many of our important markets, and more work is ongoing to widen the channels through the expansion of our commercial teams.

These combined factors will also impact the performance of the Company in the next financial year but the Board believes the medium term fundamentals remain strong, with the technology addressing broader markets. The pipeline includes substantial new orders that we hope to announce in the near future, which could materially impact our growth expectations going forward.

Whilst the Company had anticipated breaking even in the current financial year, it does not now expect to be profitable, however cash balances at the year-end continue to be strong and the Directors believe that the business has sufficient capital required to execute the business plan and deliver growth in the years ahead.

Importantly, during the last half of the year the Company has also achieved some significant efficiency improvements to its manufacturing processes, which would allow a much broader acceptance of its products in mainstream medical diagnostic markets and lower its capital investment requirements. Based on the improved manufacturing processes the Company is expanding production capability in the UK with the cost partly supported by the Regional Growth Fund.

Kromek continues to win contracts across its three target markets and has seen substantial growth in current order booking. In medical imaging, Kromek's $5.3m mutually exclusive contract for developing and supplying CZT based multispectral (colour) detectors for the CT market with one of the top four OEMs continues to progress well. During the year Kromek has also been awarded substantial contracts in the SPECT and the BMD markets.

Changes to EU legislation continue to present the Company with new opportunities within the security screening markets. The Kromek bottle scanners have now been widely adopted in the EU and continue to attract opportunities in the Asian and Middle Eastern markets.

Commenting on trading, Arnab Basu, Chief Executive of Kromek said: "I am disappointed that we will not meet market expectations but I am confident that we will harvest real value from our technology going forward. The build up of our sales and marketing resources since the IPO has been slower than expected which has also been a contributory factor in the shortfall. We have executed important commercial deals during the year and achieved significant technical developments which will lead to a much wider adoption of our products in our target markets. The demand, both for using our technology as a component and for our products remains strong and I am confident that we will continue to add substantially to our order book in the months ahead and realise value for our shareholders in the years that follow."

Kromek Chairman, Richard Morgan, added, "The management team have demonstrated their ability to rapidly grow the business and yet I know they are disappointed that growth will be slower than they had forecast. The Board is confident in the medium term prospects for Kromek and the recent advances in our technology development only add to the already substantial market opportunities to create a technology leader and a profitable and valuable business."

-Ends-

Not looking too good.

Recovery today up 10%.

New Contract Signed in Medical Imaging Market

RNS


RNS Number : 0335E

Kromek Group PLC

04 April 2014






Embargoed until: 0700hrs, 4 April 2014

Kromek Group plc

("Kromek" or "the Company")



New Contract Signed in Medical Imaging Market

for Supply of CZT Detection Modules



Kromek, a supplier of patented radiation detection technologies to the medical, security and nuclear markets, is pleased to announce that it has signed a long term contract with an established SME manufacturer of x-ray diagnostics and analysis equipment in China.

The contract grants the manufacturer preferential rights for the supply of Kromek's innovative CZT-based detection modules in China and Chinese territories. These rights are for an existing medical diagnostic application with a large market potential and the exclusive supply agreement is conditional upon minimum annual revenues to Kromek. Kromek retains full rights to the product in all other territories.

Kromek has been working with the manufacturer for the past nine months to agree the suitability and detailed structure of a long-term supply agreement. For continued exclusivity the contract provides for revenues of $1.4m and $10.2m in the Financial Years 2014-15 and 2015-16 respectively and the overall value of the contract over the next seven years is up to $159m, subject to the customer meeting its contractual revenue targets. Advanced cash payments totalling $260,000 are expected from the customer in the current Financial Year, part of which has already been received. The first supply commences in October 2014.

Commenting on the announcement, Arnab Basu, CEO of Kromek, said: "We are pleased to announce significant, further traction in the medical imaging space, particularly in a large, high growth market such as China. The signing of this contract represents further endorsement of our offering and highlights the role we can play as global medical imaging capability advances, with Kromek's technology at its heart as a key enabler."

"Kromek will continue to explore the opportunities for our technology platform in the medical imaging, nuclear detection and security screening markets and we look forward to updating shareholders as to progress in due course."



-ends-

Up another 15% this am.

Up nearly 30% now on the big contract win in China.

LISTEN: Kromek (KMK) - New contract signed in medical imaging market

Click here to listen
http://www.brrmedia.co.uk/event/122858/dr-arnab-basu-ceo

Down over 10%


Director/PDMR Shareholding

RNS


RNS Number : 2618E

Kromek Group PLC

07 April 2014






For immediate release: 7 April 2014

Kromek Group plc ("Kromek" or "the Company")

Director / PDMR shareholding

The Company was informed today that Richard Morgan, Chairman of the Company, purchased 40,000 Ordinary Shares ("Shares") of 1p each at an average of 50p per share on 07 April 2014, representing 0.04 per cent of the Company's total issued share capital.

Mr Morgan's total holding in the Company is now 372,310 Shares of 1p each, representing 0.35 per cent of the Company's total issued share capital.

Mr Morgan is also interested in Amphion Innovations plc through his Directorship in Amphion Innovations plc which holds 12,450,420 ordinary shares in Kromek being 11.6 per cent of the Company's total issued share capital.

-ends-

Contract Wins

RNS


RNS Number : 2070K

Kromek Group PLC

23 June 2014






Embargoed until: 0700hrs, 23 June 2014



Kromek Group plc



Contract Wins



Nuclear detection and Breast Cancer imaging technology



("Kromek" or "the Company")



Kromek, a supplier of patented radiation detection technologies to the medical, security and nuclear markets, is pleased to announce that it has signed a number of further contracts, in the Nuclear Detection and Medical markets.



Nuclear Detection



Kromek has been awarded a contract with the US Defense Threat Reduction Agency ("DTRA") for the design, manufacture and optimisation of high sensitivity, next generation, solid state detectors for the homeland security radiation detection market. The contract is worth $1.45 million to Kromek over the next two years and will commence in July 2014.



Commenting on the contract win, Arnab Basu, CEO of Kromek, said "Kromek is delighted to receive this award, which follows on from previous and current successful US Government programmes, and continues Kromek's strategy in leading the field in detector technology and material identification. With other potential future applications of this new technology in security, medical and civil nuclear radiation detection we believe that this programme can further cement Kromek's detector technology platforms into global growing markets".



Additionally contracts, amounting to over $950,000 to supply innovative nuclear detection products to customers in the US and around the world, have recently been signed across a broad range of clients. These contracts are in the process of being fulfilled with revenues due to Kromek now and falling in the financial year ended 2015.



Medical Imaging



Kromek has been granted contracts worth £150,000 due over of the next 12 months from the Technology Strategy Board, the UK Government's innovation agency. These are to develop an enhanced detection system for breast imaging in conjunction with the UK's Centre for Process Innovation. The project proposes to develop conformal detectors based on plastic electronic solution which can be wrapped around or inside regions of interest (e.g. breasts, limbs, suspicious packages, parts for inspection) and that the production methods will be cost competitive vs existing silicon technologies. Work on this project has already begun.



Arnab Basu added: "We continue to win new customers in our key markets, highlighting the strength of our technology and the growing adoption of the new capabilities we can offer to partners and customers across the world. We look forward to updating shareholders as to further progress from our strong pipeline in due course."



-ends-

Contract Win

RNS


RNS Number : 1000O

Kromek Group PLC

04 August 2014






Embargoed until: 07.00, 4 August 2014





Kromek Group plc

("Kromek" or "the Company")





Kromek Awarded Network Detector Development Programme by the US Defence Advanced Research Projects Agency





Kromek (AIM: KMK.L), a supplier of patented radiation detection technologies to the medical, security and nuclear markets, is pleased to announce that it has been awarded up to $1.23m for a 12-month programme with the U.S. Defense Advanced Research Projects Agency (DARPA) commencing immediately. This is to develop an advanced portable detection system for gamma and neutron radiation that can be combined in large networks, providing information on radiation signatures over an extended area. The programme is geared towards procurement in Year 2 and beyond. DARPA is an agency of the United States Department of Defense and responsible for maintaining the technological superiority of the U.S. military.



This contract, along with many others in the nuclear detection market, represents further healthy conversion of the pipeline into orders and the majority of the revenue of the contract is expected to be recognised in the current financial year.

These latest successes are rooted both in Kromek's world leading capabilities in high performance radiation detectors, which are compact and uniquely require no cooling mechanism, and also in its overall "semiconductor to solutions" business model. This allows the Company to quickly respond to emerging customer needs by understanding and integrating all the closely interlocking elements required for an end customer application. These elements often include the detector design, different system configurations and software components, to allow improved interpretation and presentation of data in an easy-to-use and efficient form. Over the last few years the Company has introduced a number of products into the nuclear detection market, each providing unique performance, field usability and reduced size, including the world's smallest, high resolution gamma ray spectrometer operating at room temperature. This is used for a wide range of applications such as nuclear decommissioning, environmental monitoring and remote sensing on board ground-based robotics and Unmanned Aerial Vehicles.

Commenting on the award, Kromek CEO Dr Arnab Basu said, "Kromek is delighted to receive this award from DARPA, which closely follows recent awards from other areas of the U.S. Government and is further recognition of the advances Kromek's detector technology platforms are making into growing global markets."



-ends-

Final Results




Operational Highlights:



§ Successful IPO providing access to wider shareholder base and platform for future growth

§ Completed successful operational integration of eV Products Inc., our second US acquisition

§ Further improvements in CZT material and detector manufacturing processes

§ 28 new patents were filed or awarded

§ Investment in expanded sales and marketing capability

§ Multiple new and significant contract wins in the medical imaging market, for CT, including a development contract with a top four OEM; in BMD; and also an agreement for the supply of imaging modules in China

§ A number of important contracts from both commercial and government customers won in the nuclear detection market

§ The start of phase 1 of the implementation of the EU regulatory framework on 31 January 2014 which is the key to sales of the Bottle Scanner product in Europe



http://www.moneyam.com/action/news/showArticle?id=4875261

UPDATE - Kromek sees greater demand

By Jamie Ashcroft

August 28 2014, 2:36pm
Kormek won significant contracts in the medical imaging market
Kormek won significant contracts in the medical imaging market


--Adds broker comment--

Kromek (LON:KMK) revealed it is seeing greater demand for its products.

The technology firm in today’s results, for the twelve months to April 30, highlighted multiple significant contract wins in the medical imaging market and agreements to supply imaging modules to China.

It also agreed contracts with both commercial and government customers for nuclear detection.

"The appetite for Kromek's components, systems and solutions in each of our target markets is increasing,” said chief executive Arnab Basu.

“The group is well placed, not only to continue to win new contracts, but also to service the growing demand for our technologies and achieve our ambition of becoming the radiation detection specialists of choice in our chosen markets.

“We have reported a number of new contracts post this period end and we are continuing to convert a strong pipeline with the current order book at an all-time high."

Panmure Gordon analyst Dr Mike Mitchell said Kromek performed ‘in line’ as he upgraded his recommendation to ‘buy’ from ‘hold.

In a note the analyst said: “While a business such as Kromek will always be subject to some element of temporal risk (such as timing on government expenditure), we believe the broader commercial positioning and a greater emphasis on budgeting/planning stands the business in good stead.”

On AIM, Kromek shares moved 0.4p (0.8%) lower at 50.1p.

Interim Results
RNS
RNS Number : 0947C
Kromek Group PLC
14 January 2015



14 January 2015



Kromek Group plc

("Kromek" or the "Company")



Interim Results



Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security and nuclear markets, announces its interim results for the six months ended 31 October 2014.



Financial Highlights

· Revenue increased 33% to £3.2m (H1 2013/14: £2.4m)

· Adjusted EBITDA* improved to £1.6m loss (H1 2013/14: £2.0m loss)

· Loss before tax was £2.3m (H1 2013/14: £2.5m loss)

· Gross margin** was 70% (H1 2013/14: 61%)

· Loss per share was 1p (H1 2013/14: 9p loss)

· Cash and cash equivalents at 31 October 2014 were £2.86m (30 April 2014: £6.56m; 31 October 2013: £9.96m), with no debt and the Company expects to be EBITDA positive for the second half of the current financial year



*Adjusted EBITDA eliminates non-recurring other income, share-based payment expenses. See 'Financial Review' below for a reconciliation of adjusted EBITDA.

**As with prior periods, gross margin is calculated before labour and overhead recovery.



Operational Highlights

· Progress achieved across all of Kromek's target sectors of medical imaging, nuclear detection and security screening, with increased sales of the Company's product portfolio while developing products and enhancing customer engagements in medical CT, SPECT and portable networkable radiation detectors

· Revenue growth as a result of higher nuclear and security product sales and US Government contracts, and supplemented by contracts with OEMs in medical imaging and sale of bottle scanners

· Successfully progressed to second year of exclusive development programme in medical CT market with a top four global OEM

· Awarded significant new opportunity by US Defense Advanced Research Projects Agency ("DARPA") with project to develop advanced portable detection system for gamma and neutron radiation that can be combined in large networks

· Key contracts won in US and UK with US Defense Threat Reduction Agency ("DTRA") and Innovate UK

· Significant contract awarded for providing bottle scanner technology to a number of airports in Asia. Over 40 airports in 10 countries now using Kromek bottle scanners

· Doubled cadmium zinc telluride ("CZT") crystal manufacturing capacity by expanding in UK, and demonstrated ability to rapidly scale up production by successfully replicating the manufacturing process previously being conducted only in US

· 10 new patents were granted and 18 new patent applications were filed during the period



Post-Period Developments

· Awarded a number of significant contracts across the business:

o $1.0m contract extension by leading global security company for developing CZT-based detectors for medical and nuclear markets, including homeland security

o First contract from another global security technology group and market leader in security solutions

o Further contract by existing customer for OEM components for baggage screening

o First contract from a leading global healthcare and diagnostics company for development of bone mineral densitometry ("BMD") applications

o Additional $1.1m contract by DARPA, as announced today, for enhancing the continued development of advanced networkable radiation detectors

· Nine patents were granted post period



Dr Arnab Basu, CEO of Kromek, said: "We are pleased to report another half year of growth against the comparative period as a result of sustained progress in Kromek's product portfolio approach whilst advancing our strategy of becoming the preferred component supplier to major OEMs in CT and SPECT and in the supply of network sensors in nuclear markets. This has been achieved both by establishing new partnerships and strengthening our existing relationships.



"Looking ahead, investment in enhancing our sales and marketing function is resulting in increased interest in Kromek's products and technology from a greater number of companies and organisations. We continue to be subject to fluctuations in the timing of certain contracts and revenue recognition as well as the impact of seasonality, with the procurement cycle of many customers resulting in sales being weighted to the second half of the current financial year. Despite this, the Company remains confident that it can deliver in excess of 100% revenue growth from the first half to second half of the current financial year. Additionally, the Company expects to be EBITDA positive for the second half of this year."

MIDAS-SHARE-TIPS-Kromek-s-scanners-stop-make-bomb.

Up 10% today.

MEET THE TECH SUPERSTARS OF TOMORROW

A 12-month share price performance of the companies that presented at the Innovators & Investors Forum last year included:

Elecosoft +42%
Idox +22%
Instem +34%
KBC Advanced +45%
XL Media +41%

The Innovators & Investors Forum, organised in partnership with Cenkos Securities and SHARES, is in its 4th year and is the UK's only technology investment show.

REGISTER NOW

Thousands of investors have attended our previous shows, attendees will also benefit from:

Learning from industry experts and influencers about the markets, the technology sector and individual companies
Find out from fund managers how they view the future in 2016
Meet the directors of up to 30 listed technology focused companies
Listen to our expert team of SHARES journalists

The event is supported with an extensive conference program
Keynote Speakers:

Daniel Coatsworth, Editor - Shares
Mark Dunne, Growth Companies Reporter - SHARES
Steven Frazer, Online Editor - SHARES
Russ Mould, Investment Director - AJ Bell
Richard Penny, Senior Fund Manager - Legal & General UK Alpha Trust
Simon Strong, Head of Research, Growth Companies - Cenkos Securities
Gervais Williams, MD - Miton Group

Further speakers to be announced soon.

Meet the teams and talk directly to CEOs and Directors from:


Advanced Oncotherapy
Abzena
Advanced Oncotherapy
ANGLE
Brady
CML Microsystems
Cyan
Eckoh
eg solutions
Flowgroup
Ilika
Instem
Kromek
Lombard Risk
Mirada
Plastics Capital
Quantum Pharma
Rosslyn Data Technologies
Selftrade
SHARES
TyraTech

Further companies to be announced soon.




Date: 2nd February 2016

Venue: Business Design Centre, London


Event timings

Registration: from 09:00
Conference: 09:45 - 17:00
Exhibition: 09:00 - 18:00



REGISTER NOW

Strong buying all week.

Oh dear, Needs more contract wins.

Director/PDMR Shareholding
RNS
RNS Number : 8156A
Kromek Group PLC
29 March 2017
 
29 March 2017
 
Kromek Group plc
("Kromek" or the "Company")
 
Director/PDMR Shareholding
 
 
Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security and nuclear markets, announces that it has received notification that, on 24 March 2017,  Berry Beumer, Chief Operating Officer of Kromek, purchased 80,000 Ordinary Shares of 1 pence each ("Ordinary Shares") in the Company at a price of 29.35 pence per share.
 
Following the purchase, Mr. Beumer has an interest in 80,000 Ordinary Shares representing 0.03% of the entire current issued share capital of the Company.

Solid buying today, looking for a bounce.

Trading Update
RNS
RNS Number : 6251D
Kromek Group PLC
28 April 2017
 
28 April 2017
 
Kromek Group plc
("Kromek" or the "Company" or the "Group")
 
Trading Update
 
Kromek, a radiation detection technology company focusing on the medical, security and nuclear markets, provides the following trading update for the year ending 30 April 2017 ahead of its full year results to be issued in July 2017.
 
The Group is making good progress on the delivery of new orders won over the past two years and, as a result, the Company is trading in line with market expectations.  
 
The Group's products continue to gain traction in all its business segments from the increasing adoption of CZT-based technology and other products. The Group expects to continue to win new customers and, together with the momentum of contract wins, it expects a step change in revenue growth in the new financial calendar year.

Good trades gone through today, due another jump.

Good 11% rise today, 34p + would be a good start.

Kromek Radiation Detectors Used During Trump Visit
RNS
RNS Number : 7432H
Kromek Group PLC
12 June 2017
 
 
12 June 2017
 
Kromek Group plc
("Kromek" or the "Company")
 
Kromek's Radiation Detectors Used by the European Commission Counter Terrorism Unit During President Trump's Visit to Brussels
 
Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security screening and nuclear markets, is pleased to announce that its next generation standalone radiation detector, D3S-ID, was deployed by European Commission Counter Terrorism Unit of Directorate General for Home Affairs in Brussels. The D3S-ID was part of security operations deployed during the NATO Security Summit and the U.S. President, Donald Trump's visit to Brussels last month.
 
The European Commission and Belgian Federal Police officers deployed D3S-ID at different locations including Brussels airport and the European Council headquarters.  Kromek was informed that the deployment was successful and its radiation detection systems performed well and met the desired high standards for accuracy and efficiency.
 
Dr Arnab Basu, Chief Executive Officer of Kromek, said: "We are delighted to be part of the security system that was deployed during President Trump's visit to Brussels. Specifically, we were pleased that the deployment was successful and that our detectors achieved the necessary high standards. We look forward to continuing our work with the European Commission, DARPA and other national law enforcement agencies to deploy our best-of-breed radiation detectors to protect people and property."
 

Await news

Reached 36.5p today, before settling at 34.88p

Going to motor, pdyor.

I've put it on my watchlist!😃

:-))

Final Results
RNS
RNS Number : 3547J
Kromek Group PLC
28 June 2017
 
28 June 2017
 
Kromek Group plc
("Kromek" or the "Group")
 
Final Results for the Year ended 30 April 2017
 
Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security screening and nuclear markets, announces its final audited results for the year ended 30 April 2017.
 
Financial Highlights
·     Revenue increased 7.5% to £9.0m (2015/16: £8.3m)
·     Product sales accounted for 74% of total revenues (2015/16: 65%), a growth year-on-year of 23%
·     Gross margin was 57% (2015/16: 53%)
·     Administration costs (including operating expenses) were £8.7m (2015/16: £8.3m)
·     EBITDA* was £1.5m loss (2015/16: £2.4m loss), following further investment of £3.5m (2015/16: £3.2m) of research costs expensed in preparation for the expected demand regarding D3S and SPECT
·     Loss before tax for the year was £3.8m (2015/16: £4.1m loss)
·     Total proceeds of £21m (£20m net of expenses) were raised as part of a Placing and Open Offer in February 2017, which saw a further 105,129,536 ordinary shares issued 
·     Cash and cash equivalents at 30 April 2017 were £20.3m (30 April 2016: £3.9m)
*EBITDA defined as earnings before interest, taxation, depreciation, amortisation and share-based payments.
 
Operational Highlights
Another year of good progress and ramp-up in commercial activities with revenue growth driven by higher product sales across Kromek's three key target markets.
 
Medical Imaging 
·     Commenced delivery on $12.6m five-year OEM contract to supply detectors for BMD diagnostics systems
·     Awarded repeat contracts by three current BMD customers worth $1.2m in total
·     Won contract worth minimum of $560,000 for the supply of radiation detectors with an existing customer
·     Continued to make progress on the development of CZT-based SPECT modules for customer in China
 
Nuclear Detection
·     Delivered 10,000 D3S units in support of DARPA's SIGMA programme
o D3S sensors were field-tested in Washington DC and currently deployed by New Jersey Port Authority
·     Awarded $1.6m two-year agreement from DTRA to develop a ruggedised high performance isotope radiation detector for military use
·     Won and delivered a $430,000 contract to supply nuclear radiation detection products to the UK Ministry of Defence
 
Security Screening
·     Secured five-year agreement, worth a minimum of $3.1m, from an existing US-based customer
·     Awarded 12-month contract, valued at $990,000, together with a ten-year exclusivity agreement, by an existing US-based customer to develop and supply upgraded detectors
·     Awarded and delivered a contract for the Group's bottle scanners from an Asian airport group 
 
Six new patents were filed and 11 granted during the period.
 
Dr Arnab Basu, CEO of Kromek, said: "We are pleased with the growth in revenues this year, reflecting the delivery of long-term contracts won in previous years and contracts won during the year. Kromek is at the leading-edge in developing commercially-viable radiation detection solutions and this has, in turn, enabled our customers to successfully launch their new generation of clearly differentiated products in a wide range of markets. Consequently, revenues from the sale of our products now accounts for nearly three quarters of our revenues.
 
"In the 2017/18 fiscal year, Kromek is seeing a step change across all its business segments as we continue to execute on the large-scale contracts that have been secured over the last 24 months. Additionally, we expect OEM customers to launch products incorporating our technology, prompting additional orders to be placed as sales of these products accelerate. As a result, the Group expects to report year-on-year revenue growth of approximately 40%, in-line with market expectations."

Out before close, not good enough.

Down by over a third in the last year , but results out today look encouraging.

2 July 2018

Kromek Group plc

("Kromek" or the "Group")



Final Results for the Year ended 30 April 2018



Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security screening and nuclear markets, announces its final audited results for the year ended 30 April 2018.



Financial Highlights

· Revenue increased 32% to £11.8m (2016/17: £9.0m)

· Product sales accounted for 81% of total revenues (2016/17: 74%), a growth year-on-year of 44%

· Gross margin was 56.4% (2016/17: 57.1%)

· EBITDA* was £0.5m profit (2016/17: £1.5m loss)

· Loss before tax for the year was £2.5m (2016/17: £3.8m loss)

· Cash and cash equivalents at 30 April 2018 were £9.5m (31 October 2017: £15m)

*EBITDA defined as earnings before interest, taxation, depreciation, amortisation, other income and share-based payments. For a reconciliation, see the Financial Review below.



Operational Highlights



· Milestone year as revenue growth from ramp-up in commercial activities enabled Kromek to achieve EBITDA positive for the first time

· Growth due to continued delivery on previously-signed agreements as well as commencing delivery on new high-value contracts won during the year

· Secured new purpose-built premises for Kromek's US operations in Pittsburgh, which will enable the facility to become a world-leading manufacturer of SPECT cameras



Medical Imaging

The Group's CZT-based SPECT cameras and BMD detectors produce superior quality and higher resolution digital images that significantly advance the early identification of disease, such as cancer, dementia and osteoporosis.

· Secured a five-year contract, worth a minimum of $5.38m, to incorporate Kromek's CZT-based detector modules in a new osteoporosis product offering for an existing BMD customer

· Awarded a three-year £1.4m programme by Innovate UK to deliver a Low Dose Molecular Breast Imaging Device based upon the Group'-s CZT-based SPECT detectors

· Won a five-year repeat order, post-period end, worth $1.2m, from an existing medical customer for the supply of gamma detector modules for incorporation in the customer's products

· Advanced towards achieving first clinical validation of Kromek's CZT-based SPECT detector system



Nuclear Detection

The D3S is the world's most advanced, portable, nuclear radiation detection device used by counter-terrorist agencies to protect civilians and key infrastructure in cities, including ports, borders and transport hubs. Kromek's portfolio also includes a range of high resolution detectors and measurement systems for the civil nuclear markets used in nuclear power plants, research and for other applications.

· Awarded a $1.6m extension to its DARPA contract to add further technical innovation capability to the Kromek D3S family of equipment

· D3S continued to be deployed and field-tested in major areas in the US by DARPA, and by other public administrations across the globe, including by European authorities during the visit of the President of the United States to Brussels in May 2017

· Named as a qualified contractor under the $8.2bn U.S. Department of Defense IDIQ for the Joint Enterprise - Research, Development, Acquisition, and Production/Procurement contract award vehicle following extensive due diligence

· Strengthening and expansion of distribution channels in the civil nuclear markets, and completion of deployment of Quant for GR1 product in all UK EDF nuclear power plants



Security Screening

The Group's security screening solutions are being incorporated into the next generation liquid and luggage scanners. These upgraded machines are replacing legacy machines and are enhancing the safety of passengers while minimising the inconvenience of the security process at airports.

· Commenced work on the Group's first long-term security screening contract: a five-year, $3.1m agreement with an existing US-based customer to provide OEM components for baggage screening products used in aviation security

· Won a five-year, $2.0m contract, from a new OEM customer, which has commenced incorporating Kromek's technology into its baggage security screening systems to enhance detection of an extensive range of threat materials



Seven new patents were filed and 29 granted during the period.



Dr Arnab Basu, CEO of Kromek, said: "I am very pleased to report that Kromek had another good year of delivering revenue growth and developing our customer base who continue to launch next generation products incorporating our advanced radiation detectors. We also achieved one of our key targets for the year by becoming EBITDA positive for the first time in our history. This is an important milestone towards cash flow breakeven and pre-tax profits.



"Looking ahead, the momentum of the 2017/18 financial year has been sustained into the current financial year as Kromek's products continue to gain traction in all of our target markets from the increasing adoption of CZT-based technology and other products. We continue to win new customers and, together with executing on previously-won contracts, Kromek expects to deliver growth across its business segments and to report continued revenue growth for 2018/19 in line with market expectations."

Kromek wins two new contracts in medical division
RNS
RNS Number : 2245Y
Kromek Group PLC
20 August 2018

20 August 2018

Kromek Group plc
("Kromek" or the "Company")

Kromek wins two new contracts in medical division
New OEM customer and a repeat contract from existing BMD customer underscores momentum in medical imaging sector

Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security and nuclear markets, is pleased to announce that it has secured two contracts, worth a total of $1 million, with a new OEM customer and an existing Bone Mineral Densitometry (BMD) customer. Both contracts commence immediately, with one delivered over an 18-month period and the other within the current financial year.

In the nuclear medicine instrumentation field, Kromek has been awarded a $700k order from a new OEM customer to supply its proprietary Cadmium Zinc Telluride (CZT) detectors to be used in the nuclear medicine market. The Company's technology will provide higher resolution detection capabilities enabling better patient outcomes. This contract will be delivered over an 18-month period starting immediately.

In the Bone Mineral Densitometry market, Kromek has received a repeat contract of $340k for CZT-based detectors for the customer's existing product line. This further re-enforces the run rate of this product group with all revenue from this contract to be recorded in the current financial year.

Dr Arnab Basu, CEO of Kromek, commented: "We continue to add new OEM customers in the medical device sector, working with them to build the next generation of medical instrumentation. Our CZT technology in medical scanners delivers excellent quality images and detection capability that lead to a better patient outcome. We also build strong and long-lasting partnerships with our clients, as highlighted by today's repeat contract with another OEM in the BMD sector to supply CZT-based detection units for their equipment."